Low level ß-lactamase production in methicillin-resistant staphylococcus aureus strains with ß-lactam antibiotics-induced vancomycin resistance by Yuriko Hirao et al.
Hirao et al. BMC Microbiology 2012, 12:69
http://www.biomedcentral.com/1471-2180/12/69RESEARCH ARTICLE Open AccessLow level β-lactamase production in methicillin-
resistant staphylococcus aureus strains with
β-lactam antibiotics-induced vancomycin
resistance
Yuriko Hirao1,2,3, Yurika Ikeda-Dantsuji1, Hidehito Matsui1, Masaki Yoshida4, Seiji Hori4, Keisuke Sunakawa2,
Taiji Nakae1 and Hideaki Hanaki1*Abstract
Background: A class of methicillin-resistant Staphylococcus aureus (MRSA) shows resistance to vancomycin only in
the presence of β-lactam antibiotics (BIVR). This type of vancomycin resistance is mainly attributable to the rapid
depletion of free vancomycin in the presence of β-lactam antibiotics. This means that β-lactam antibiotics remain
active or intact in BIVR culture, although most MRSA cells are assumed to produce β-lactamase. We hypothesised
that the BIVR cells either did not harbour the β-lactamase gene, blaZ, or the gene was quiescent. We tested this
hypothesis by determining β-lactamase activity and conducting PCR amplification of blaZ.
Results: Five randomly selected laboratory stock BIVR strains showed an undetectable level of β-lactamase activity
and were blaZ-negative. Five non-BIVR stock strains showed an average β-lactamase activity of 2.59 ± 0.35 U. To test
freshly isolated MRSA, 353 clinical isolates were collected from 11 regionally distant hospitals. Among 25 BIVR
strains, only 16% and 8% were blaZ positive and β-lactamase-positive, respectively. In contrast, 95% and 61% of 328
non-BIVR strains had the blaZ gene and produced active β-lactamase, respectively. To know the mechanism of low
β-lactamase activity in the BIVR cells, they were transformed with the plasmid carrying the blaZ gene. The
transformants still showed a low level of β-lactamase activity that was several orders of magnitude lower than that
of blaZ-positive non-BIVR cells. Presence of the β-lactamase gene in the transformants was tested by PCR
amplification of blaZ using 11 pairs of primers covering the entire blaZ sequence. Yield of the PCR products was
consistently low compared with that using blaZ-positive non-BIVR cells. Nucleotide sequencing of blaZ in one of
the BIVR transformants revealed 10 amino acid substitutions. Thus, it is likely that the β-lactamase gene was
modified in the BIVR cells to downregulate active β-lactamase production.
Conclusions: We concluded that BIVR cells gain vancomycin resistance by the elimination or inactivation of β-
lactamase production, thereby preserving β-lactam antibiotics in milieu, stimulating peptidoglycan metabolism, and
depleting free vancomycin to a level below the minimum inhibitory concentration of vancomycin.
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Individuals whose immune activity has been compro-
mised by conditions, such as cancer, transplantation,
blood dialysis, and aging often become infected with
Staphylococcus aureus. Particularly problematic is infec-
tion by methicillin-resistant S. aureus (MRSA), for which
antibiotic chemotherapy is often difficult and results in
failure because this organism shows resistance to struc-
turally and functionally diverse chemotherapeutic agents.
Spread of MRSA was limited to hospital patients for a
long period of time, but it has become more common in
the broader community in recent years. Owing to the
multi-antibiotic-resistant nature of MRSA, only a limited
range of chemotherapeutic agents can be used; most
commonly, vancomycin or the recently developed line-
zolid [1-3].
Vancomycin is a glycopeptide antibiotic with a mo-
lecular mass of 1449.3. It binds with the D-Ala-D-Ala
terminals of the peptidoglycan structure and its precur-
sors, and blocks the action of peptidoglycan transpepti-
dase or penicillin-binding proteins (PBPs), consequently
inhibiting extension of the peptidoglycan network and
growth of the cells [4,5]. Vancomycin is active against
Gram-positive bacteria including enterococci and
staphylococci [6], whereas it is ineffective against Gram-
negative bacteria, mainly because the outer membrane
acts as a penetration barrier.
Another problem in MRSA-infected patients is co-
infection with Gram-negative bacteria, such as
Pseudomonas aeruginosa, which is naturally resistant to
vancomycin and linezolid. One of the solutions for the
chemotherapy of such mixed infections has been to use
a combination of vancomycin and β-lactam antibiotics
[7]. In fact, this regime has been recommended for sev-
eral decades in Japan and seems to be successful [8].
However, the use of this combination therapy has led to
the emergence of MRSA that is resistant to vancomycin
only in the presence of β-lactam antibiotics, which is
designated as BIVR [9,10].
BIVR is understood to have arisen because the use of
β-lactam antibiotics promotes peptidoglycan metabol-
ism, probably due to partial β-lactam-mediated damage
of the peptidoglycan networks [11]. The affected cells
upregulate the peptidoglycan biosynthetic pathways and
repair systems, producing large amounts of peptidogly-
can precursors, such as lipid-intermediate II with free
D-Ala-D-Ala terminals [12,13]. Vancomycin tightly
binds with the D-Ala-D-Ala structure of peptidoglycan
and its intermediate precursors [4,5]. Consequently, the
concentration of free vancomycin in milieu is lowered
below its MIC and the cells begin to grow under such
conditions [13].
The enzyme, β-lactamase hydrolyses the β-lactam ring
of β-lactam antibiotics and inactivates them, therebyrendering the cells resistant to β-lactam antibiotics.
Staphylococcus cells that have not been exposed to β-
lactam antibiotics do not possess the β-lactamase gene,
blaZ, and hence, are highly susceptible to β-lactam anti-
biotics. However, clinical use of β-lactam antibiotics
enables the cells to harbour a plasmid bearing blaZ that
encodes cell-associated penicillinase. These cells have
two main emergency responses: one is to induce β-
lactamase and the other is to elicit the peptidoglycan re-
cycling and repair system [14].
We generally assume that most MRSA cells are resist-
ant to β-lactam antibiotics owing mainly to the produc-
tion of β-lactamase [15] or of PBP2′ (or PBP2a) [16-18].
Therefore, β-lactam antibiotics in MRSA culture are
readily hydrolysed. However, the BIVR phenomenon is
induced only in the presence of β-lactam antibiotics,
suggesting that β-lactam antibiotics in culture remain in-
tact. An empirical observation is that clinical isolates of
BIVR cells seem to have a low level of β-lactamase activ-
ity compared with that of non-BIVR MRSA. Accord-
ingly, we hypothesised that β-lactamase activity in BIVR
cells was somehow downregulated, which prompted us
to investigate the relationship between the BIVR
phenomenon and β-lactamase activity.
Results
Properties of the representative laboratory BIVR and non-
BIVR cells
BIVR is a class of MRSA that is susceptible to vancomycin
at ≤2 μg/ml, and becomes vancomycin-resistant in the
presence of β-lactam antibiotics. We tested our stock
strains used in this study for the BIVR phenomenon.
Strains Mu3, K101, K638, K670, K744 and K2480 were
streaked on Mu3 agar plates impregnated with 4 μg/ml
vancomycin. None of these strains grew on the plates, con-
firming that the BIVR cells were vancomycin-susceptible.
The MICs of vancomycin for these strains were 1–2 μg/ml
(Table 1). When β-lactam impregnated disks with concen-
trations of 0.1, 1.0 and 10 μg/ml ceftizoxime (Astellas
Pharma, Tokyo, Japan) were placed on the plates, all the
strains grew around the disks (Figure 1, only K744 and
K2480 are shown). Thus, the BIVR property in the labora-
tory stock strains was confirmed.
Cells classified as non-BIVR MRSA, which were the
K1, K27, K51,K54, K1179 and N315 strains, were tested
similarly. These cells were vancomycin-susceptible and
did not grow on the vancomycin-containing plates in
the presence or absence of β-lactam-impregnated disks
(Figure 1, K1179). The MICs of vancomycin for these
strains were 0.5–2 μg/ml.
β-lactamase activity in BIVR and non-BIVR cells
Based on our hypothesis that BIVR cells might express a
low level of β-lactamase, we compared the enzyme activity
Table 1 MIC of antibiotics in the strains used in this study
(μg/ml)
Strain MPIPC IPM VAN LZD ABPC ZOX CAZ
Reference strains
FDA209P (MSSA) 0.5 ≤0.25 0.5 2 0.25 4 16
N315 (non-BIVR) 32 1 0.5 2 32 >128 128
Mu3 (BIVR) >128 64 2 2 32 >128 >128
Lab. stock non-BIVR
K1 >128 128 2 2 64 >128 >128
K27 >128 64 2 2 64 >128 >128
K51 >128 128 2 2 64 >128 >128
K54 >128 64 1 2 64 >128 >128
K1179 64 16 1 2 32 >128 >128
Lab. stock BIVR
K101 >128 64 2 2 32 >128 >128
K638 >128 128 2 2 32 >128 >128
K670 >128 128 2 2 32 >128 >128
K744 >128 128 1 2 16 >128 >128
K2480 >128 64 1 2 32 >128 >128
Transformants
K744-T >128 >128 1 1 16 >128 >128
K2480-T >128 128 0.5 2 32 >128 >128
MPIPC, oxacillin; IPM, imipenem; VAN, vancomycin; LZD, linezolid; ABPC,
ampicillin; ZOX, ceftizoxime; CAZ, ceftazidime.
Table 2 β-Lactamase activity and presence of blaZ in
laboratory-stock BIVR and non-BIVR strains
Strains blaZ β-lactamase activity
(μmol/min/mg protein)
Reference strains
FDA209P (MSSA) - <1 × 10-4
N315 (non-BIVR) + 7.39 × 10-1
Mu3 (BIVR) - <1 × 10-4
BIVR strains
K101 - <1 × 10-4
K638 - <1 × 10-4
K670 - <1 × 10-4
K744 - <1 × 10-4
K2480 - <1 × 10-4
Non-BIVR strains
K1 + 1.94 × 10-1
K27 + 1.27 × 10-1
K51 + 6.24 × 10-1
K54 + 11.1
K1179 + 9.06 × 10-1
Transformants
K744-T + <1 × 10-4
K2480-T + <1 × 10-4
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http://www.biomedcentral.com/1471-2180/12/69in five laboratory stock non-BIVR and BIVR strains. The
β-lactamase activity in non-BIVR strains ranged from
0.127 to 11.1 U (Table 2) with an average value of
2.59± 0.35 U, while that in all five BIVR strains showed an
undetectable level of β-lactamase, <10–4 U. Thus, it be-
came evident that β-lactamase activity in BIVR cells wasFigure 1 BIVR test of the representative strains. The class of MRSA and
photographs of the representative strains and the lower panels show the r
non-BIVR MRSA harbouring the blaZ gene and producing a high level of β
the concentration of ceftizoxime in the disk.at least three orders of magnitude lower than that in non-
BIVR cells. The following explanations are offered: (i) the
non-BIVR cells harboured a plasmid bearing the β-
lactamase gene (blaZ), but the BIVR cells did not; or (ii)
both BIVR and non-BIVR cells harboured a blaZ-bearing
plasmid, but the production of active β-lactamase in BIVR
cells was suppressed or downregulated.the strain number are shown in the figure. Upper panels show
espective transformants with the plasmid pN315. K1179 was a
-lactamase. Hence, a transformant was not available. xx μg/ml denotes
Figure 2 Agarose gel electrophoretograms of the PCR product.
Primer K was used for the PCR of blaZ and the conditions for the
thermal cycler setting are given in the text. A fixed agarose
concentration (2%) was used. The gel was stained with GelRed and
visualised under UV light. Marker, LowRange 100 bp DNA markers;
FDA209P, negative control; N315, positive control; the MRSA class
and strain number are shown in the figure.
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was amplified by PCR using a primer set K shown in
Table 3. N315 and FDA209P cells were used as positive
and negative references, respectively. As seen in Figure 2,
the PCR products amplified from N315 cells showed a
large distinct band with nucleotide numbers correspond-
ing to about 170 bp, which was the expected PCR prod-
uct. The PCR product was undetectable when the
FDA209P DNA was used as a template. Similarly, PCR
was carried out using the template DNA from Mu3,
K101, K638, K670, K744 and K2480 cells and no detect-
able band was found (Figure 2). The results suggested
that these BIVR strains did not have the β-lactamase
gene, which was fully consistent with the finding of un-
detectable β-lactamase activity. In contrast, PCR experi-
ments using the DNA template from non-BIVR strains
showed clear bands corresponding to the expected blaZ
product. These results were again consistent with that of
the β-lactamase assay and with the above explanation
(i); whether or not BIVR cells possessed the gene encod-
ing β-lactamase, but did not give the answer to the
above question (ii); whether the expression of the β-
lactamase gene in BIVR could be suppressed. Therefore,
the following experiments were conducted.
Transformation of BIVR cells with a plasmid bearing the
β-lactamase gene
To test whether the β-lactamase gene was stable in the
BIVR cells and expressed active enzyme, the BIVR cells
were transformed with the plasmid carrying blaZ. Plas-
mid DNA was extracted from N315 cells (bearing the
pN315 plasmid) cultured in 5.0 ml brain–heart infusion
broth and purified by the Plasmid Mini kit (Qiagen,
Tokyo, Japan). The average yield of DNA appeared to be
~50 ng. To confirm that the extracts contained theTable 3 Primer sets used
Code Nucleotide sequence
A (F) 5’-GGTTGCTGATAAAAGTGGTCAA-3’(R) 5’-CTCGAAAATAATAAAGG
B (F) 5’-AAGAAATCGGTGGAATCAAAAA-3’(R) 5’-GTTCAGATTGGCCCTTA
C (F) 5’-TTGCCTATGCTTCGACTTCA-3’(R) 5’-GCAGCAGGCGTTGAAGTAT
D (F) 5’-TCAAACAGTTCACATGCCAAA-3’(R) 5’-TTTTTGATTCCACCGATTT
E (F) 5’-GCCATTTTGACACCTTCTTTC-3’(R) 5’-CGAAGCATAGGCAAATCTC
F (F) 5’-TGAGGCTTCAATGACATATAGTGATAA-3’(R) 5’-GTTCAGATTGGC
G (F) 5’-TGTTTAATAATAAAAACGGAGACACTT-3’(R) 5’-TCAACTTATCATT
H (F) 5’-AAGAAATCGGTGGAATCAAAAA-3’(R) 5’-TTTAAAGTCTTGCCGAA
I (F) 5’-AAGAAATCGGTGGAATCAAAAA-3’(R) 5’-TCGAAAATAATAAAGG
J (F) 5’-GCCATTTTGACACCTTCTTTC-3’(R) 5’-AGCAGCAGGCGTTGAAGTA
K* (F) 5’-ACTTCAACACCTGCTGCTTTC-3’(R) 5’-TGACCACTTTTATCAGCAA
* Primer K was from reference [19].
F and R denote the forward and reverse sequences, respectively.
Codes correspond with that in Figure 3.plasmid bearing the β-lactamase gene, they were sub-
jected to PCR amplification using the primer set K.
Agarose gel electrophoresis clearly showed a single dis-
tinct large band corresponding to the size of the
expected PCR product (similar to the result in Figure 2,
Ref. N315). Attempts have been made to extract the
plasmid DNA from BIVR cells, such as K744 and five
other strains, but the yield was consistently undetectable
except for the K2480 cells, which showed a trace amount
of DNA. PCR amplification of blaZ taking the K2840
extracts as the template yielded no visible band.
The BIVR cells, K744 and K2480, were transformed
with plasmid DNA extracted from N315 cells. Selection
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forehand to a certain extent. Thus, transformants were
selected on agar plates impregnated with a 1.5-fold MIC
equivalent of ampicillin and obtained from K744 and
K2480 strains (K744-T and K2480-T, respectively). Pres-
ence of the blaZ gene in the K744-T and K2480-T cells
was confirmed by PCR using whole-cell extracts as the
template, and subsequent agarose gel electrophoresis
yielded a single DNA band corresponding to that
obtained from N315 cells (Figure 3). Note that the
amount of PCR products using K744-T and K2480-T
DNA as the template appeared low compared with that
from N315 cells (Figure 3). The identity of untransformedFigure 3 PCR products of the blaZ gene. The primer sets in
alphabetical order correspond with that in Table 2. Agarose gel
electrophoresis was carried out as described in the legend to
Figure 2. Only a part of the electrophoretogram is shown. Arrow
and bp, the amplicon size; N315, K744-T and K2480-T were the
source of the template DNA.and transformed cells was confirmed by pulse-field gel
electrophoresis of the chromosomal DNA treated with
SmaI. Unsuccessful attempts were made to transform
FDA209P with the pN315 plasmid. The reasons for failure
of this transformation experiment remain obscure.
β-lactamase activity was determined using N315,
K744-T and K2480-T cells. The results showed that ac-
tivity in N315 cells appeared to be 0.74 U, while the
levels in K744-T and K2480-T cells were undetectable
(Table 2). Plasmid DNA from K744-T was undetectable,
but a trace amount was extracted from K2480-T com-
parable with the level from the untransformed parent
cells. Attempts have been made to amplify the blaZ
DNA using the column eluate of the extracts as the tem-
plate. The PCR product using the K744-T extracts was
undetectable and that of K2480-T showed a faint band,
which was identical with the control experiment using
untransformed K2480. We interpreted these results to
mean that the BIVR cells might have a mechanism to
modify the β-lactamase gene. The transformants were
subjected to the BIVR test. K744-T and K2480-T cells
showed a strong BIVR reaction in the presence of 0.1,
1.0 and 10 μg/ml ceftizoxime (Figure 1), confirming that
the BIVR property was unchanged even in the presence
of modified blaZ.
Search for mutations in the blaZ gene of the
transformants
One of the possibilities for low β-lactamase activity in
the BIVR transformants could be that the β-lactamase
gene could have mutations or is somehow modified.
Experiments were carried out to amplify and sequence
blaZ using 11 different pairs of primers (Table 3) cover-
ing the entire blaZ sequence. As K744-T DNA or
K2480-T DNA was used as a template, the yield of PCR
product was consistently low in all the experiments (Fig-
ure 3). However, attempts were made to determine their
nucleotide sequences comparing with the sequence from
pN315 (the blaZ sequence in our experiments appeared
identical to that of the database). Nucleotide sequencing
of the PCR products from the K744-T template showed
10 amino acid substitutions at Val9Ala, Ser22Pro,
Val86Ile, Glu145Gly, Lys193Glu, Asn196Lys, Phe203Leu,
Asn207Ser, Pro217Ser and Tyr220Cys compared with
the blaZ sequence on pN315 (Figure 4). Nucleotide se-
quencing of the products using the K2480-T templates
could not be completed owing to the poor yield of PCR
products (Figure 3). Therefore, it is not clear whether or
not blaZ in K2840-T had mutations. However, it was
strongly suggested that blaZ in K2480-T was modified
because the amount of PCR product was consistently
low or undetectable in some cases using 11 different
pairs of primers, compared with the amount of PCR
product from N315 cells (Figure 3).
N315      MKKLIFLIVI ALVLSACNSN SSHAKELNDL EKKYNAHIGV YALDTKSGKE    50
K744-T    --------A- ---------- -P-------- ---------- ----------    50
K2480-T   ---------- ---------- ---------- ---------- ----------    50
N315      VKFNSDKRFA YASTSKAINS AILLEQVPYN KLNKKVHINK DDIVAYSPIL   100
K744-T    ---------- ---------- ---------- -----I---- ----------   100
K2480-T   ---------- ---------- ---------- ---------- ----------   100
N315      EKYVGKDITL KELIEASMTY SDNTANNKII KEIGGIKKVK QRLKELGDKV   150
K744-T    ---------- ---------- ---------- ----XX---- ----G-----   150
K2480-T   ---------- ---XXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX   150
N315      TNPVRYEIEL NYYSPKSKKD TSTPAAFGKT LNKLIANGKL SKKNKNFLLD   200
K744-T    ---------- ---------- ---------- ---------- --E--K----   200
K2480-T   XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXX------- -X--------   200
N315      LMFNNKNGDT LIKDGVPKDY KVADKSGQAI TYASRNDVAF VYPKGQSEPI   250
K744-T    --L---S--- ------S--C ---------- ---------- ----------   250
K2480-T   ------X--- ---------- ---------- ---------- ----------   250
N315      VLVIFTNKDN KSDKPNDKLI SETAKSVMKE F   281
K744-T    ---------- ---------- ---------- -   281
K2480-T   ---------- ---------- ---------- -   281
Figure 4 Amino acid sequence of the blaZ gene in the transformant. The blaZ gene in the transformants K744-T and K2480-T as well as that
of the donor plasmid pN315 was amplified by PCR using the primer pairs listed in Table 2. The nucleotide sequence was determined by the
dideoxy chain termination method at Nippon Gene Research Laboratories (Miyagi, Japan). The nucleotide sequence was aligned by the computer
programme, DNASIS Pro (Hitachi Software Engineering Co., Ltd., Tokyo, Japan), and was converted to the amino acid sequence. Amino acids are
expressed by a single letter code. X mark denotes the amino acid residue, which could not be specified in this study. – denotes the amino acid
residue, which is identical to that of pN315.
Table 4 Presence of blaZ gene and β-lactamase activity in
clinical isolates of BIVR and non-BIVR strains
blaZ Nitrocefin test
+ - + -
BIVR 4 (16.0%) 21 (84.0%) 2 (8.0%) 23 (92.0%)
Non-BIVR 310 (94.5%) 18 (5.5%) 200 (61.0%) 128 (39.0%)
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http://www.biomedcentral.com/1471-2180/12/69Taken together, these findings indicated that introduc-
tion of the blaZ gene into BIVR cells did not elevate the
β-lactamase activity nor had much influence on the BIVR
property, which might have been due to modification of
the blaZ gene in the transformants. Therefore, these find-
ings support the prediction that the β-lactamase gene was
downregulated or modified in BIVR cells.
β-lactamase activity and occurrence of the blaZ gene in
clinical isolates of BIVR and non-BIVR MRSA
The above results were obtained using laboratory stock
strains. To determine whether a similar tendency would be
seen in fresh clinical isolates, we collected a total of 353
strains of independently isolated MRSA from 11 regionally
distant hospitals. Twenty-five strains were classified as
BIVR, which was equivalent to 7.0% of the total, while 328
strains (92.9%) were non-BIVR. All these strains were sub-
jected to the blaZ test by PCR and a qualitative β-
lactamase test using a nitrocefin-impregnated disk. Among
the 25 BIVR strains, 21 (84.0%) were blaZ-negative and 23
(92.0%) yielded negative results for the nitrocefin test
(Table 4). Among the non-BIVR strains, 310 (94.5%) were
blaZ-positive and only 18 (5.5%) were blaZ-negative. Simi-
larly, 223 strains (61.0%) yielded positive results for the
nitrocefin test and the remaining 128 (39.0%) gave negative
results (Table 4). A statistically significant difference in the
occurrence of the blaZ gene and β-lactamase activitybetween the BIVR and non-BIVR strains was found with a
probability <0.01 by the χ2 and Fisher’s tests. These results
clearly showed a trend for BIVR cells to lack the β-
lactamase gene and not produce active β-lactamase,
whereas most non-BIVR cells possessed the blaZ gene and
a significant fraction (61.0%) produced β-lactamase. It
should be noted that the nitrocefin test is a qualitative assay
and might not be sensitive enough to detect low levels of β-
lactamase. To investigate this possibility, we randomly
selected 10 non-BIVR strains that were blaZ-positive and -
negative for the nitrocefin test and carried out a quantita-
tive β-lactamase assay. All cells produced a low level of β-
lactamase ranging from 2.74×10–3 to 2.1×10–2 U with an
average of 7.25×10–3 ±1.25×10–2 U (Table 5). Therefore,
the number of β-lactamase-positive strains must be much
higher.
Ten randomly selected non-BIVR strains that were
blaZ-positive and positive for the nitrocefin test were sub-
jected to the quantitative β-lactamase assay. The activity
Table 5 Quantitative β-lactamase activity, nitrocefin test
and presence of blaZ in randomly selected clinical





BIVR(n = 5) - - <1 × 10-4 <1 × 10-4
Non-BIVR
(n = 10)
+ + 1.03 × 10-3 – 4.48 0.79 ± 1.84
Non-BIVR
(n = 10)
+ - 2.76 × 10-4
– 2.13 × 10-2
7.28 × 10-3
± 1.25 × 10-2
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http://www.biomedcentral.com/1471-2180/12/69ranged from 0.103 to 0.103×10–3 U with an average of
0.79± 1.84 U. Thus, it is likely that most non-BIVR cells
produced β-lactamase. Activity in BIVR cells (blaZ-nega-
tive and nitrocefin-test-negative) was undetectable.Discussion
This paper addressed the question of whether BIVR cells
possess the blaZ gene and produce active β-lactamase
because BIVR cells show resistance to vancomycin only
in the presence of β-lactam antibiotics. This means that
β-lactam antibiotics must remain active in the BIVR mi-
lieu. Tests using laboratory stock strains revealed that all
BIVR cells lacked blaZ and showed an undetectable level
of β-lactamase activity. All the laboratory stock non-
BIVR cells possessed blaZ and produced high levels of
β-lactamase. This trend was confirmed using 353 clinical
isolates including 25 BIVR and 325 non-BIVR strains.
Transformation of the BIVR cells with a plasmid bearing
blaZ revealed that: (i) β-lactamase activity was undetect-
able; (ii) an attempt to extract the plasmid bearing blaZ
was unsuccessful; (iii) PCR amplification of blaZ yielded
a very low level of products in all 11 experiments using
11 different primer sets; and (iv) the nucleotide sequence
of the PCR products using the K744-T template revealed
10 amino acid substitutions.
A plausible explanation of the results is that a low or
undetectable level of β-lactamase in BIVR cells enables
β-lactam antibiotics to remain active, thereby promoting
peptidoglycan metabolism and the repair system produ-
cing large amounts of peptidoglycan precursors with un-
bound D-Ala-D-Ala terminals [4,5]. The precursors bind
with free vancomycin, lowering the vancomycin concen-
tration in milieu below the MIC of vancomycin. The
BIVR cells begin to grow under these conditions, result-
ing in vancomycin resistance.
In the presence of β-lactam antibiotics, a bacterial cell
probably detects the peptidoglycan fragments generated
by the β-lactam action and might respond by producing
β-lactamase or promoting the peptidoglycan biosyn-
thetic cascade and repair system [14]. Switching from
one response to the other is assumed to be regulated by
the balance of two peptidoglycan intermediates, such asanhMurNAc-tripeptide and UDP-MurNac-pentapeptide;
a scenario reported in Escherichia coli [14].
If this scenario is applicable to S. aureus cells, BIVR
and non-BIVR may be explained as follows. In the pres-
ence of β-lactam antibiotics, MRSA cells, which have
cryptic mutations to promote peptidoglycan metabolism,
produce large amounts of peptidoglycan intermediates
and deplete free vancomycin. S. aureus responding in
this way may be BIVR. In contrast, in the presence of β-
lactam antibiotics, MRSA cells with a wild-type level of
peptidoglycan metabolism undergo activation of the β-
lactamase-producing pathway. They may be the
vancomycin-susceptible non-BIVR MRSA. However, this
interpretation does not explain the discovery reported in
this study that BIVR cells tend to exclude the plasmid
bearing the β-lactamase gene, and downregulate the pro-
duction of active β-lactamase, probably modifying the
blaZ gene. These observations may be accounted for by
suggesting that BIVR cells exclude blaZ or do not pro-
duce active β-lactamase to maintain intact β-lactam
antibiotics in milieu to promote peptidoglycan metabol-
ism. If β-lactam antibiotics are hydrolyzed by the β-
lactamase, upregulated peptidoglycan metabolism would
cease and the cell would be killed immediately by
vancomycin.
To find a solution for the treatment of BIVR infection,
we conducted serial passage experiments of BIVR cells
in an antibiotic-free medium for several consecutive days
and tested the fate of the BIVR cells. Figure 5 shows the
BIVR test of the cells subjected for serial passage in the
antibiotic-free medium. For the sake of space, only one
strain each of the laboratory stock BIVR (K744) and
freshly isolated clinical BIVR (K724) was presented. The
BIVR cell properties were phased out by 5 consecutive
days of passages. These cells, whose BIVR properties
were gradually phased out, showed the non-BIVR
phenotype when subjected to the BIVR test again. The
mechanism of phasing out was not investigated further.
The lesson from this experiment is that, once BIVR cells
are isolated from patients, the use of β-lactam antibiotics
should be terminated for a while until the BIVR cells are
phased out, and another type of antibiotic effective
against Gram-negative bacteria should be used.
Conclusions
A class of S. aureus, which shows vancomycin resistance
only in the presence of β-lactam antibiotics (BIVR), was
tested for the presence of the β-lactamase gene (blaZ)
by PCR, and for the production of active β-lactamase.
The rationale for this study was that β-lactam antibiotics
in BIVR culture must be preserved to induce vanco-
mycin resistance. However, it is generally assumed that
the majority of MRSA strains harbour a plasmid bearing
blaZ and produce active β-lactamase. Five randomly
Figure 5 Phase-out of the BIVR phenomenon. BIVR cells were transferred to antibiotic-free MH agar and the plate was incubated at 37°C for
24 h. Cell suspensions from the plates were inoculated again on antibiotic-free MH agar and incubated for 24 h at 37°C. This serial transfer and
culture was continued for 5 consecutive days. The culture was subjected to the BIVR test every day. Only a representative strain from the
laboratory stock BIVR, K744 and freshly isolated clinical strains, K725, is presented. 1st to 5th represents the cycle of passage in the antibiotic-free
medium.
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of either blaZ or β-lactamase activity, whereas five non-
BIVR laboratory strains possessed blaZ, and produced
β-lactamase at an average level of 2.59 U. Among 353
strains of freshly isolated MRSA, 25 and 325 were BIVR
and non-BIVR, respectively. Of the 25 BIVR strains, only
four (16%) and two (8%) strains were blaZ-positive and
yielded a positive result for the β-lactamase test, respect-
ively. Among the non-BIVR strains, 310 (94.5%) and
>200 (>61%) were blaZ-positive and yielded a positive
result for the β-lactamase test. Transformation of BIVR
cells with a plasmid bearing blaZ still showed an un-
detectable level of β-lactamase activity that probably was
due to modification of the transformed blaZ gene. These
results clearly demonstrate that the majority of BIVR
cells do not produce active β-lactamase either by avoid-
ing harbouring of the blaZ gene or by modification of
blaZ that preserves β-lactam antibiotics in the BIVR mi-
lieu and induces vancomycin resistance.
Methods
Bacterial strains used and culture conditions
The bacterial strains used for antibiotic-susceptible S.
aureus and a representative BIVR strain were FDA209P
and Mu3 [20], respectively. The MICs of vancomycin in
FDA209P and Mu3 were 0.5 μg/ml and 2 μg/ml, re-
spectively, and those of ceftizoxime were 4 μg/ml and
>128 μg/ml, respectively (Table 1). Representative BIVR
and non-BIVR strains from this laboratory were K744
and K1179, respectively, and their properties have been
reported previously [13]. Four additional strains each of
BIVR and non-BIVR were also used. N315 is a strain
harbouring plasmids that bear the β-lactamase gene as
reported previously [21], and was used as the source of
the β-lactamase gene. A total of 353 strains of MRSA
were collected from clinical sources and subjected to the
BIVR and β-lactamase tests. Culture media used were
Mueller–Hinton (MH) broth (Becton–Dickinson, Tokyo,
Japan), Mu3 agar (Becton–Dickinson) and MH agar(Becton–Dickinson), depending on the purpose, and
cells were incubated at 35°C for the desired period of
time.
BIVR test
BIVR was defined according to an earlier report [10,22].
Briefly, MRSA cells were grown in MH broth overnight at
35°C in the presence of 1 μg/ml ceftizoxime and 0.1 ml
aliquots of cell suspensions adjusted to A1cm578 ¼ 0:3 was
streaked on an Mu3 agar plate impregnated with 4 μg/ml
vancomycin. An 8-mm paper disk impregnated with 80 μl
0.1, 1.0 or 10.0 μg/ml ceftizoxime was placed on the agar
plate. Cells showing a growth zone around the disk were
judged to be BIVR.
PCR
The blaZ genes encoding β-lactamase were amplified by
PCR with the following thermal cycler settings: 98°C for
30 s for the initial denaturation and then 30 cycles of de-
naturation, annealing and extension at 98°C for 5 s, 57°C
for 10 s and 72°C for 10 s, respectively. A primer pair used
for blaZ detection is listed in Table 2. Phusion DNA poly-
merase (Finzymes, Espoo, Finland) was used. The PCR
products were analysed by agarose gel electrophoresis and
visualised by staining with GelRed (Biotim Hayward, CA,
USA). The marker used was LowRange 100bp DNA
ladder marker (Norgen Bioteck Corp, Toronto, Canada).
Determination of β-lactamase activity
Beta-lactamase activity was determined either by the
paper disk or spectrophotometric method [23]. For the
semi-quantitative assay, an 8-mm paper disk impreg-
nated with 80 μl 550 μg/ml nitrocefin was placed on col-
onies on the agar plate. The cells that developed a pink
to red colour within 30 min were judged to be β-
lactamase-positive. The quantitative β-lactamase assay
was carried out as follows. Bacterial cells were grown
overnight at 37°C in a 4-ml L-broth supplemented with
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harvested by centrifugation at 10 000 × g for 10 min.
Pellets were washed once with a 4-ml aliquot of 50 mM
sodium phosphate buffer, pH 7.2, containing 145 mM
sodium chloride, and were suspended in 400 μl of the
same buffer. Over 99% of the β-lactamase was associated
with the centrifuged cell pellets, and therefore the assay
was carried out using the washed cell suspension. A pair
of 1.0-ml reaction mixtures was prepared containing
10 μl cell suspension, 10 μl 100 mM EDTA and 880 μl
50 mM sodium phosphate buffer, pH 7.0. The reaction
was initiated by adding 100 μl 500 μM nitrocefin, and
one tube was incubated for 3 min and the other for
13 min. The tubes were centrifuged at 12 000 × g for
2 min, and clear supernatant was separated. A486 was
determined at 5 and 15 min. Reaction velocity per mi-
nute was calculated by subtracting A486 at 5 min from
that at 15 min divided by 10. Colour development from
5 to 15 min appeared linear under the conditions. For
the cells with low β-lactamase activity, 100 μl cell sus-
pension was used and incubated at 24°C for 30 min.
One unit of the enzymatic activity was defined as μmol
nitrocefin hydrolysis/min/mg protein.
Quantification of cellular protein
Cell suspensions were mixed with 2.0% of sodium dode-
cyl sulphate, and the mixture was heated at 100°C for
5 min and then centrifuged at 12 000 × g for 5 min. Pro-
tein concentration in the clear supernatant was deter-
mined using the BioRad Protein Assay kit (BioRad,
Hercules, CA, USA) according to the manufacturer’s
instructions.
Determination of MIC of antibiotics
The MIC of antibiotics was determined by the agar dilu-
tion method according to the Clinical and Laboratory
Standards Institute manual [24].
Extraction of plasmid DNA
Bacterial cells were grown overnight in 5.0 ml brain–
heart infusion broth (Becton–Dickinson) containing
10 μg/ml ceftizoxime, and harvested by centrifugation at
6000 × g for 10 min. Cells were treated with 50 μg/ml
lysostaphin at 37°C for 40 min. Plasmid DNA was
extracted using the Qiagen Plasmid Mini kit, according
to the manufacturer’s instructions. DNA was analysed by
agarose gel electrophoresis (1.0%), stained with GelRed
and visualised under UV light.
Transformation experiments
Transformation-competent cells were prepared accord-
ing to the manufacturer’s instructions of the MicroPulser
(BioRad). Transformation experiments were carried out
using 250 ng DNA and the MicroPulser according to themanufacturer’s instructions. Transformants were selected
on agar plates impregnated with a 1.5-fold MIC equivalent
of ampicillin.
Statistical analysis
The χ2 and Fisher’s tests were carried out using a com-
puter programme embedded in Microsoft Excel.
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